📊 CLDX Key Takeaways
Investment Thesis
Celldex Therapeutics is a pre-revenue biotech company in severe financial distress with $1.5M in revenue (down 78% YoY), massive operating losses of $287.4M, and negative free cash flow of $213.7M. The company is burning cash at an unsustainable rate with only $28.9M in liquidity against $210.9M in negative operating cash flow, indicating critical runway concerns despite strong balance sheet equity.
CLDX Strengths
- Strong balance sheet with $527.2M in stockholders' equity providing strategic cushion
- Minimal debt burden with zero long-term debt and clean capital structure
- Adequate current ratio of 10.49x indicating short-term liquidity despite cash burn
CLDX Risks
- Catastrophic cash burn of $210.9M from operations with only $28.9M cash remaining; estimated runway of less than 2 months
- Revenue collapse of 78% YoY to $1.5M suggests failed commercialization or terminated programs
- Unsustainable negative margins with -18,600% operating margin and -16,748% net margin indicating core business model failure
Key Metrics to Watch
- Cash burn rate and quarterly cash position relative to remaining runway
- Revenue stabilization or recovery from current $1.5M annualized rate
- Pipeline milestone announcements and clinical trial progression for biotech programs
CLDX Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 10.49x current ratio provides a solid financial cushion.
CLDX Profitability Ratios
CLDX vs Default Sector
How Celldex Therapeutics, Inc. compares to Default sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
CLDX Balance Sheet & Liquidity
CLDX 5-Year Financial Trend
5-Year Trend Summary: Celldex Therapeutics, Inc.'s revenue has remained relatively flat over the 5-year period, with a 5% decline. The most recent EPS of $-2.92 indicates the company is currently unprofitable.
CLDX Growth Metrics (YoY)
CLDX Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $1.4M | -$32.8M | $-0.64 |
| Q2 2025 | $730.0K | -$32.8M | $-0.54 |
| Q1 2025 | $156.0K | N/A | $-0.56 |
| Q3 2024 | $1.5M | N/A | $-0.64 |
| Q2 2024 | $268.0K | N/A | $-0.54 |
| Q1 2024 | $156.0K | N/A | $-0.56 |
| Q3 2023 | $407.0K | N/A | $-0.57 |
| Q2 2023 | $163.0K | N/A | $-0.65 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
CLDX Capital Allocation
CLDX SEC Filings
Access official SEC EDGAR filings for Celldex Therapeutics, Inc. (CIK: 0000744218)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CLDX
What is the AI rating for CLDX?
Celldex Therapeutics, Inc. (CLDX) has an AI rating of STRONG SELL with 95% confidence, based on fundamental analysis of SEC EDGAR filings.
What are CLDX's key strengths?
Strong balance sheet with $527.2M in stockholders' equity providing strategic cushion. Minimal debt burden with zero long-term debt and clean capital structure.
What are the risks of investing in CLDX?
Catastrophic cash burn of $210.9M from operations with only $28.9M cash remaining; estimated runway of less than 2 months. Revenue collapse of 78% YoY to $1.5M suggests failed commercialization or terminated programs.
What is CLDX's revenue and growth?
Celldex Therapeutics, Inc. reported revenue of $1.5M.
Does CLDX pay dividends?
Celldex Therapeutics, Inc. does not currently pay dividends.
Where can I find CLDX SEC filings?
Official SEC filings for Celldex Therapeutics, Inc. (CIK: 0000744218) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CLDX's EPS?
Celldex Therapeutics, Inc. has a diluted EPS of $-3.90.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.